Algorithms for Optimizing the Treatment of Depression: Making the Right Decision at the Right Time

Pharmacopsychiatry

Volumn 36, Issue SUPPL. 3, 2003, Pages

  Adli, M ^a   Rush, A J ^b   Moller H J ^c   Bauer, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALGORITHM; BIPOLAR DEPRESSION; CONFERENCE PAPER; DECISION MAKING; DEMOGRAPHY; EDUCATION; ELECTROCONVULSIVE THERAPY; ELECTRONIC MEDICAL RECORD; EXPERIENCE; FAMILY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PHYSICIAN; PRIORITY JOURNAL; TIME; TRAINING;

ALGORITHMS; ANTIDEPRESSIVE AGENTS; CLINICAL PROTOCOLS; DECISION MAKING; DECISION TREES; DEPRESSIVE DISORDER; DISEASE PROGRESSION; HUMANS;

EID: 0347269050     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Adli M, Berghöfer A, Linden M, Helmchen H, Müller- Oerlinghausen B, Mackert A, Stamm T; Bauer M. Effectiveness and feasibility of a standardized stepwise drug treatment algorithm for inpatients with depressive disorders - results of a two-year observational study. J Clin Psychiatr 2002; 63: 782-790
2. Adli M, Kießlinger U, Linden M, Neu P, Smolka M, Bauer M. Evaluation of a Systematic Treatment Algorithm for Depressive Disorders: How Effective Are the Different Treatment Steps? A Randomized Controlled Study by the Berlin Algorithm Study Group [abstract]. 154th Annual Meeting, American Psychiatric Association, May 5-10, 2001 New Orleans, USA:
3. Agency for Health Care Policy and Research (AHCPR). Treatment of depression - newer pharmacotherapies. Summary, evidence report/ Technology Assessment: No. 7. AHCPR pub. No. 99-0580. Rockville, MD: 1999
4. Bauer M, Adli M, Kiesslinger U, Neu P, Smolka M, Linden M. Algorithm-guided treatment vs. treatment as usual: randomized trial in inpatients with depression [abstract]. 154th Annual Meeting. American Psychiatric Association, May 5-10, 2001 New Orleans, USA
5. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatr 2002; 3: 5-43
6. Bauer M, Döpfmer S. Lithium augmentation in treatment-resistant depression - a meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19: 427-434
7. Bech P, Rafaelsen OJ. The melancholia scale: development, consistency, validity and utility. In Sartorius N, Ban TA, eds. Assessment of Depression Berlin Heidelberg: Springer, 1986: 259-269
8. Faltermaier-Temizel M, Laakmann G, Baghai T, Kuhn K. Prädiktive Faktoren für den Therapieerfolg beim depressiven Syndrom. Nervenarzt 1997; 68: 62-66
9. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF, Kupfer DJ. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 2003; 26: 457-494
10. Flint AJ, Rifat SL. The effect of sequential antidepressant treatment on geriatric depression. J Affect Dis 1996; 36: 95-105
11. Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatr 2000; 61: 9-15
12. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatr 1993; 54: 405-418
13. Hawley CJ, Pattinson HA, Quick SJ, Echlin D, Smith V, McPhee S, Sivakumaran T. A protocol for the pharmacologic treatment of major depression. A field test of a potential prototype. J Affect Dis 1998; 47: 87-96
14. Helmchen H. Current trends of research on antidepressive treatment and prophylaxis. Compr Psychiat 1979; 20: 201-214
15. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatr 1998; 55: 694-700
16. Katon W, Von Korff M, Lin E, Walker E, Simon GE, Bush T, Robinson P, Russo J. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA 1995; 273: 1026-1031
17. Klerman GL, Weissman MM. The course, morbidity, and costs of depression. Arch Gen Psychiatr 1992; 49: 831-834
18. Lavori PW, Rush AJ, Wisniewski S, Alpert J, Fava M, Kupfer DJ, Nierenberg A, Quitkin FM, Sackeim HA, Thase ME, Trivedi M. Strengthening clinical effectiveness trials: Equipoise-stratified randomization. Biol Psychiatr 2001; 50: 792-801
19. Linden M. Therapeutic standards in psychopharmacology and medical decision making. Pharmacopsychiat 1994; 27 (suppl): 41-45
20. Linden M, Helmchen H, Mackert A, Müller-Oerlinghausen B. Structure and feasibility of a standardized stepwise drug treatment regimen (SSTR) for depressed inpatients. Pharmacopsychiat 1994; 27 (suppl): 51-53
21. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and functional capacity to work. Arch Gen Psychiatr 1992; 49: 761-768
22. Möller HJ. Therapieresistenz unter Antidepressiva: Definition, Epidemiologie und Risikofaktoren. In: Bauer M, Berghöfer A, eds. Therapie-resistente Depressionen - Aktueller Wissensstand und Leitlinien für die Behandlung in Klinik und Praxis Berlin Heidelberg New York: Springer, 1997: 3-15
23. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-1442
24. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatr 1990; 51 (6, suppl): 39-47
25. Nolen WA, Haffmans J. Treatment of resistant depression. Review on the efficacy of various biological treatments, specifically in major depression resistant to cyclic antidepressants. Int Clin Psychopharmacol 1989; 4: 217-228
26. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25: 1171-1180
27. Paykel ES, Scott J, Teasdale JD, Johnson AL, Garland A, Moore R, Jenaway A, Cornwall PL, Hayhurst H, Abbott R, Pope M. Prevention of relapse in residual depression by cognitive therapy. A controlled trial. Arch Gen Psychiatr 1999; 56: 829-835
28. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatr 1993; 50: 85-94
29. Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SP, Suppes T, Miller AL, Trivedi MH, Swann AC, Biggs MM, Shores-Wilson K, Kashner TM, Pigott T, Chiles JA, Gilbert DA, Altshuler KZ. Medication treatment for the severely and persistently ill: the Texas medication algorithm project. J Clin Psychiatry 1999; 60: 284-291
30. Rush AJ. Preface. In: Rush AJ, ed. Mood Disorders. Systematic Medication Management. Modern Problems of Pharmacopsychiatry; Vol. 25 Basel: Karger, 1997: VIIVIII
31. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The inventory of depressive symptomatology (IDS): Psychometric properties. Psychol Med 1996; 26: 477-486
32. Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Trivedi M, Suppes T, Miller AL, Biggs MM, Shores-Wilson K, Witte B, Shon SP, Rago WV, Altshuler KZ. Texas Medication Algorithm Project, Phase 3 (TMAP-3): Rationale and Study Design. J Clin Psychiatry 2003; 64: 357-69
33. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi M, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart J, McGrath PJ, Biggs MM, Shores-Wilson K, O'Neal BL, Lebowitz BD, Ritz AL, Niederehe G, for the STAR*D Investigators Group. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials, in press
34. Thase ME, Rush AJ. Treatment-resistant depression. In Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress New York: Raven Press, 1995: 1081-1097
35. Trivedi MH, Rush AJ, MD, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Key T, Biggs MM, Shores-Wilson K, Witte B, Suppes T, Miller AL, Altshuler KZ, Shon SP. Texas Medication Algorithm Project (TMAP): Clinical Results for Patients with Major Depressive Disorder. Submitted,
36. Ware JE, Kosinski M, Keller SD. A 12-item short form health survey (SF-12): construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-233